Clinical trial · Interventional
Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy
NCT00129597CI-TRIAL-00000635unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prevalence of chronic pain after mastectomy is beyond 50% 3 months after surgery. This pain is related to a sensitization of the central nervous system through N-methyl-D-asparate (NMDA) receptors. Ketalar might prevent the occurrence of chronic pain by anti-NMDA properties after mastectomy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ketalar | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- To evaluate the effect of perioperative ketalar on pain intensity 3 months after a mastectomy
- measure
- Pain intensity is evaluated by an appropriate questionnaire 1 and 3 months after surgery.
Secondary outcomes (1)
- measure
- To evaluate the incidence of chronic pain after mastectomy, the impact on life quality, and the area of hyperalgesia
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Mastectomy in patients 18 to 80 years old Exclusion Criteria: * American Society of Anesthesiology (ASA) class \>= 3 * Renal, heart or hepatic failure * Allergy to ketalar * Psychiatric disease * Chronic antalgic treatment
References
Publications (0)
Data not yet available
No reference posted for this study.